Psychedelics Without Hallucinations? Study Identifies Possible Antidepressants In LSD-Like Molecules
Novo Nordisk Joins NLRP3 Bandwagon, Bets $70M On Ventus' Lead Drug Candidate
2 days ago
Alzamend Neuro Seeks FDA Nod For Dementia Immunotherapy Study
2 days ago
Biohaven's ALS Drug Fails To Meet Study Endpoint, Second Therapy To Fail Trials In Recent Months
2 days ago
Silence Therapeutics' Thalassemia Hopeful Shows Favorable Safety Profile In Early Stage Study
2 days agoBiotech Recent News
Galecto's Myelofibrosis Candidate Reduces Bone Marrow Fibrosis
Regeneron-Sanofi's Flagship Dupixent Becomes First FDA-Approved Treatment For Prurigo Nodularis
Idera Pharma Acquires Rare Disease Player, Names New CEO
MorphoSys' Monjuvi Shows Long-Term Durable Response In Blood Cancer Settings
Axcella Shares Jump Despite Mixed Bag Data From Mid-Stage NASH Trial
Kiora Pharma is Starting Human Trials of a Novel Treatment That Could Restore Vision In Patients With Inherited Blindness
Aligos Co-Founders File Complaint Against Johnson & Johnson Alleging Fraud
Windtree Therapeutics Stock Surges After Positive Istaroxime Data In Cardiogenic Shock
Atara Biotherapeutics to Receive Additional Near-Term Milestone Under Updated Tab-cel Commercialization Pact
Merck Inks Supply Deal With Sinopharm To Commercialize COVID-19 Pills In China
Gilead's Investigation Reveals Two Kingpins Directly Associated With Fake HIV Medications Scheme
Medical Implants Could One Day Be Made Of CBD Or Poly Cannabinoids, According To New Study
These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win
What The Biogen Chart Reveals As Stock Rallies Hard On Alzheimer's Data
PepGen's Duchenne Candidate Has Potential For Greater Exon Skipping Capabilities At Lower Doses Versus Sarepta's Candidate, Says Analyst
MaxCyte Inks Platform License With Vertex For Gene-Editing Program For Rare Blood Disorders
Rallybio's Thrombocytopenia Candidate Shows Rapid, Complete Elimination Of Transfused Platelets
SAB Biotherapeutics Unveils New Data From COVID-19 Programs Reinforcing Efficacy Against Variants
This Analyst Believes Biogen's Lecanemab Data Not 'Slam Dunk' For Complete CMS Approval
Aquestive Inks Supply Pact For Its Seizure Treatment Covering European, Middle East Countries
KemPharm's Lead Prodrug Shows Favorable Safety Profile For Rare Sleeping Disorder
OraSure Secures BARDA Funding For Next-Gen Ebola Diagnostic Test
ASLAN Pharmaceuticals Presents New Data From Atopic Dermatitis Candidate